Premium
Chimeric antigen receptor T‐cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia
Author(s) -
Moskop Amy,
Pommert Lauren,
Thakrar Pooja,
Talano Julie,
Phelan Rachel
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28739
Subject(s) - medicine , chimeric antigen receptor , leukemia , refractory (planetary science) , cancer research , antigen , oncology , immunology , immunotherapy , immune system , physics , astrobiology
Chimeric antigen receptor (CAR) T‐cells, engineered autologous T‐cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements ( KMT2A r) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T‐cell product approved for relapsed/refractory ALL, in a patient with KMT2A r infant ALL who was treated for combined marrow and extramedullary (renal) relapse.